Article

Neuroprotective implant for treatment of glaucoma in phase II trial

Author(s):

Julianne Mobilian
Conferences|ASCRS

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
Related Content
Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa
March 26th 2025

Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial
March 24th 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants
March 23rd 2025

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement
March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

© 2025 MJH Life Sciences

All rights reserved.